ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2009

Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.

Koen van Besien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.